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(F= 3.16 and F= 3.15). The results from the regression model showed that as age 
increases, the expenditure rises especially at old ages. Patients from lower income 
groups spent more on ambulatory services than those in higher income groups, as 
well as individuals living in regions with very high level of social exclusion. Among 
other main determinants, individuals that looked for private health care attention 
along with those that perceived their health problems as severe increased their 
health expenditure. ConClusions: Out of pocket expenditure has been regres-
sive among health care users at IMSS. Therefore especial attention to lower income 
patients should be paid.
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objeCtives: Advanced Therapy Medicinal Products (ATMPs) include innovative 
and regenerative therapies such as gene therapy, somatic cell therapy medicinal 
product, and tissue engineered product. They represent major opportunity for curing 
many chronic disabling diseases. About 300 clinical trials for ATMPs are ongoing. 
Should some of these therapies reach their goal, which is considered to be likely, 
the impact on already constraint public payer budget would be dramatic. The objec-
tive of this project was to assess yearly cost of ATMPs for payers assuming a pay 
for performance split over years as long as disease do not re-emerge. Methods: 
We reviewed the economic impact of curing a range of chronic disabling conditions 
with ATMPs. We assumed that some ATMPs might cure a disease through one treat-
ment cycle. We computed cost per QALY by considering the avoided cost as well 
as disability associated to the diseases. We assumed a cost per QALY of £30,000/
QALY. We considered the payment will be based on yearly basis for each patient 
and not at the time of drug administration. This payment scheme was chosen as 
drug cost might not be affordable through a single payment. Results: Results 
showed that payment for ATMPs would range from about £10,000 to £480,000 per 
year and per cured patient depending on conditions. Avoided costs represented the 
main driver of the yearly ATMPs price, while generated QALY was comparatively 
smaller. These yearly payments are among the highest for rare disease driven by 
orphan drug prices avoided, while they are the lowest for chronic conditions with 
episodic clinical manifestation such as depression (assuming a recurrence every 5 
years). ConClusions: ATMPs cost might represent a source of important financial 
liability for public payers in a short future. This study raised awareness about need 
for new payment schemes for ATMPs and new sources of funding.
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objeCtives: To provide cost estimates and implications of irrational prescrib-
ing habits under the national health insurance scheme in the Kintampo North 
Municipality of rural Ghana. Methods: A retrospective cross sectional study car-
ried out for the whole of 2012. Vetted outpatient department claim forms submitted 
by all facilities to the Kintampo Municipal Mutual Health Insurance Scheme were 
used. Cost of all drugs and antibiotics per claim form were computed for four ran-
domly selected months of March, May, September and December to represent the 
first, second, third and fourth quarters of the year respectively. Results: A total of 
4238 claim forms were reviewed with a total of 12415 drugs prescribed within the 
period. The average costs of all drugs and antibiotics per prescription was GH¢ 4.50 
($ 2.25) and GH¢ 1.08 ($ 0.54) respectively. The average cost of antibiotics constituted 
24% of the average total cost of drugs per prescription. The average cost of all drugs 
and antibiotics was higher in private facilities (GH¢6.05 and GH¢1.34 respectively) 
than public facilities (GH¢ 3.65 and GH¢0.93 respectively). The difference in average 
cost of all drugs and antibiotics between private and public facilities was significant 
(p< 0.001each). The expected percentage average cost savings of all drugs and anti-
biotics assuming rational prescribing would have been more than 31.1% and 17.6% 
respectively. ConClusions: Average cost of drugs and antibiotics were high in this 
setting. Significant level of cost savings can be achieved if prescribing is optimal as 
recommended by the WHO.
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objeCtives: In Egypt, the Ministry of Health and Population (MOHP) sets phar-
maceutical prices from ex-factory to retail. In July 2012, the pricing policy changed 
from a cost plus to an external reference pricing method which was effective in 
October 2012. Our goal was to quantify the policy change impact on retail prices in 
pharmacies. Methods: We used MOHP lists and IMS data to pre-identify products 
with price changes. Purchase and sales data were obtained from a chain phar-
macy in Alexandria for all transactions pre- and post- the policy change (April-
Jun 2012 and 2013) to identify additional products and to validate the MOHP and 
IMS data. Changes in price per unit and per daily defined dose (DDD) were calcu-
lated. Results: A total of 205 products were subject to price changes, 70% were 
generics and 36% were essential drugs. The main therapeutic classes represented 
by the products were anti-infectives 15%, cardiovascular 14%, hair products 12%, 
vaginal-antiseptic 10%, psychotropics 8%, blood products 7% and analgesics 6%. 
Half of the products were produced by domestic private companies, 27% by mul-
tinational firms, 21% by state-owned companies and 2% were imported. Overall, 
the average price per physical unit increased by 53% (54% per DDD) for the affected 
n= 19). ConClusions: Manufacturer listed prices for oral formulations of NMEs 
at market entry are increasing over time. Orphan and priority review drugs have 
significant higher prices at market entry than other drugs.
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objeCtives: Pharmacoeconomic studies often require estimating the cost of drugs 
using manufacturer listed prices. There is a lack of studies assessing the relation-
ship between actual prices and manufacturer listed prices. This study compared 
the average sales price (ASP) and the average wholesale price (AWP) of single source 
brand drugs reimbursed by Medicare Part B for drugs used in physician offices 
in 2012. Methods: ASP data for the four quarters of 2012 were extracted from 
the Centers of Medicare and Medicaid Services (CMS) webpage, AWP data from 
the RedBook (Truven Health Analytics, Inc.) and drug information from the FDA 
website. Descriptive statistics and 95% confidence intervals were used in the analy-
sis. Results: CMS listed 571 products reimbursed by Medicare Part B in 2012. There 
were 243 (42.6% ) products with complete ASP and AWP information and without 
generic competition, of those 60.5% were new drugs applications (NDA), 22.2% thera-
peutic biologics (BLA), 12.8% other biologics, and 4.5% vaccines. The average ASP 
was 73.9%±34.5% the AWP in the first quarter of 2012, 72.4%±22.9% in the second 
quarter, 72.0%±24.5% in the third quarter, and 72.3%±26.5% in the fourth quarter. The 
relationship ASP/AWP in the fourth quarter was: 76.3%±89.0% (95%CI: 71.3%-81.3%, 
n= 147) for NDAs, 82.5%±9.6% (95%CI: 80.0%-85.1%, n= 54) for BLAs, 75.4%±38.9% 
(95%CI: 68.2%-82.7%, n= 31) for other biologics, 64.6%±18.6% (95%CI: 53.6%-75.6%, 
n= 11 )for vaccines, and 77.0%±70.7% (95%CI: 73.7%-80.4%, n= 243) for all products 
combined. ConClusions: The use of AWP overestimates the actual manufacturer 
average sales prices. ASP represented approximately 72% of the AWP across all 
products. This relationship was larger could explain the differences between actual 
and manufacturer listed prices.
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objeCtives: Elevated body temperature in critical care patients can increase 
complications and resource use. Automated targeted temperature management 
devices can be effective treatments for controlling patient temperature. This study 
estimated the cost impact of an innovative surface cooling system, the Arctic Sun® 
Temperature Management System, vs. alternative cooling methods (e.g., blankets 
and wraps), in critical care. Methods: A decision analytic model quantified the 
cost impact of Arctic Sun® vs. alternative cooling methods from a U.S. hospital 
perspective. An indirect comparison was conducted to inform the proportion of 
patients achieving target temperature. Based on a review of observational and ran-
domized studies, length of stay in the intensive care unit (ICU) and hospital ward 
stay were calculated for patients with and without elevated body temperature. 
Utilizing data from several critical care subgroups, it was estimated that 43% of 
patients are targeted for cooling. Medicare costs were assigned to hospital days, 
with average diagnosis-related group reimbursement integrated within the model. 
Acquisition costs included annual capital equipment assuming 5 year deprecia-
tion and disposables. One-year budget impact was estimated for 1,000 annual ICU 
patients. Results: Length of stay for ICU and ward days per patient was calculated 
for each comparator as follows: Arctic Sun® [2.07, 4.61] and alternative [2.54, 4.92]. 
Results predicted that use of Arctic Sun® vs. alternative cooling methods could save 
approximately $482,760 USD annually. Considering average reimbursement, these 
cost savings translate into a hospital margin per patient of $1,110. Sensitivity analy-
ses including nursing time predicted further cost savings (i.e., an additional $268,070 
per year). Results were robust to several alternative assumptions. ConClusions: 
This analysis suggests that use of Arctic Sun® in critical care patients may result 
in improved patient care and important cost-savings for U.S. hospitals. Additional 
data is required to further substantiate the relationship between resource utiliza-
tion and temperature cooling.
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objeCtives: The aim of this study is to identify the determinants of out of pocket 
expenditure, defined as the spending on physician visits, drugs and laboratory and 
ancillary tests, among users of the ambulatory health services at IMSS. Methods: 
Data from the National Health Survey 2012 was used to estimate the total and 
mean out of pocket expenditure among ambulatory health care users. A statisti-
cal analysis to test for differences in the mean expenditure with gender, age and 
income was performed. A multiple regression model was carried out to identify 
the impact of factors associated with out of pocket payments made by the users 
of these services. Results: 29% of health care users that reported any type of out 
of pocket spending were affiliated at IMSS. Among them, the total and mean out 
of pocket expenditure was of USD$ 29,259 and USD$15 respectively. The highest 
expenditure was associated with the physician visits (61%), followed by the spending 
on laboratory and ancillary services (30%) and drugs (9%). There was not a statisti-
cally significant difference between gender and total expenditure (t= 0.24). On the 
contrary a significant statistical difference was found with groups of age and income 
